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Congenital Diaphragmatic hernia (CDH) is a condition characterized by a defect in the diaphragm leading to
protrusion of abdominal contents into the thoracic cavity interfering with normal development of the lungs.
The defect may range from a small aperture in the posterior muscle rim to complete absence of diaphragm.
The pathophysiology of CDH is a combination of lung hypoplasia and immaturity associated with persistent
pulmonary hypertension of newborn (PPHN) and cardiac dysfunction. Prenatal assessment of lung to head ratio
(LHR) and position of the liver by ultrasound are used to diagnose and predict outcomes. Delivery of infants with
CDH is recommended close to term gestation. Immediate management at birth includes bowel decompression,
avoidance of mask ventilation and endotracheal tube placement if required. The main focus of management
includes gentle ventilation, hemodynamic monitoring and treatment of pulmonary hypertension followed by
surgery. Although inhaled nitric oxide is not approved by FDA for the treatment of PPHN induced by CDH, it is
commonly used.
Extracorporeal membrane oxygenation (ECMO) is typically considered after failure of conventional medical
management for infants ≥ 34 weeks’ gestation or with weight >2 kg with CDH and no associated major lethal
anomalies. Multiple factors such as prematurity, associated abnormalities, severity of PPHN, type of repair and need
for ECMO can affect the survival of an infant with CDH. With advances in the management of CDH, the overall
survival has improved and has been reported to be 70-90% in non-ECMO infants and up to 50% in infants who
undergo ECMO.
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Congenital Diaphragmatic hernia (CDH) is characterized
by a defect in the diaphragm leading to the protrusion of
abdominal contents into the thoracic cavity affecting the
normal development of the lungs. The condition may
present as an isolated lesion or as part of a syndrome.
The incidence of CDH based on the available literature
ranges from approximately 0.8 - 5/10,000 births and
varies across the population [1–4]. There is slightly
higher male predominance and a lower risk of isolated
CDH reported among African-Americans [3, 5]. In spite
of advances made in the medical and surgical man-
agement of CDH, the mortality and morbidity remain* Correspondence: pkchandr@buffalo.edu
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of stay in the hospital requiring multi-disciplinary
approach for their management and follow-up after
hospital discharge.Review
Etiology
The etiology of CDH largely remains unclear and cur-
rently is thought to be multifactorial. The majority of
the cases have an isolated diaphragmatic defect present-
ing with pulmonary hypoplasia and persistent pulmonary
hypertension of newborn (PPHN). CDH can be associ-
ated with cardiac, gastrointestinal, genitourinary anomal-
ies or with chromosomal aneuploidy such as trisomies.
Multiple genetic factors along with environmental expo-
sures and nutritional deficiencies have been proposed to
be the possible etiologies for CDH [9–11]. Studies inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Fig. 2 Size of the defect – The size of the defect may vary between
small (A) to diaphragmatic agenesis (D). Defects B & C are
considered moderate to large (Tsao et al. 2008). (Copyright
Satyan Lakshminrusimha)
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Vitamin A pathway [12]. Nitrofen, a herbicide, when
administered to pregnant rodents, results in CDH in
the majority of offspring [13, 14]. Similar effects were
seen in WT1 and COUP-TFII mutant mouse models.
Studies in neonates with CDH have shown low retinol
and retinol-binding protein levels from cord blood
samples [9, 15].
Pathology
Location (Fig. 1): Postero-lateral hernias also known as
Bochdalek hernias are the most common type (70–75%)
with the majority occurring on the left side (85%) and
less frequently on the right side (13%) or bilateral (2%).
Anterior defects or Morgagni hernias (23–28%) and cen-
tral hernias (2–7%) are the other types [16, 17].
Size (Fig. 2): The diaphragm begins to develop at
approximately 4 weeks of gestation and is fully formed
by 12 weeks [18]. The defect may range from a small
opening of the posterior muscle rim to complete absence
of diaphragm.
The embryologic basis of CDH remains controversial.
It was thought initially that the defect happened second-
ary to failure of different parts of the diaphragm to fuse
resulting in a patent pleuroperitoneal canal [19, 20]. Rat
models have shown a defect in the primordial diaphragm
called the pleuroperitoneal fold [16]. This, in turn, allows
the gut to enter the thoracic cavity when it returns fromFig. 1 Classification of CDH based on location of the diaphragmatic
hernias: Most common type of hernias are the posterior lateral
hernias (70–75%) also known as Bochdalek hernias, with majority
occurring on the left side (85%) and less frequently on the right side
(13%) or bilateral (2%). Other types of hernias are the anterior
defects or Morgagni hernias (23–28%) followed by the rare central
hernias (2–7%). (Copyright Satyan Lakshminrusimha)the extraembryonic coelom of the umbilicus. Another
speculation is that lung hypoplasia may be the primary
causal factor in the pathophysiology of diaphragmatic
hernia [21]. If the development of lung bud is disturbed,
there is an impaired development of a post hepatic mes-
enchymal plate (PHMP) that is closely related to the
development of lung, resulting in a defective diaphragm
[21]. Evidence from electron microscopy in a rat model
[22] of CDH further supports the fact that when the
development of the PHMP is impaired, a diaphragmatic
defect occurs.
A weakness in the diaphragm can cause diaphragmatic
eventration and may be mistaken for a diaphragmatic
hernia. Diaphragmatic eventration is more common on
the right side and is not associated with severe lung
hypoplasia. While a complete absence of the diaphragm
may occur resulting in diaphragmatic agenesis and se-
vere lung hypoplasia. Irrespective of the basis, a defect
in the diaphragm causes the abdominal viscera to herni-
ate into the thoracic cavity resulting in abnormal lung
development. The defect also leads to abnormal fetal
breathing movements resulting in the void of stretch-
induced lung maturation [16]. Thus the major underlying
pathophysiology of CDH appears to be a combination of
lung immaturity and hypoplasia that leads to PPHN. This
may be further aggravated by left ventricular underdevel-
opment and right ventricular hypertrophy resulting in
ventricular dysfunction [23–26].
Lung hypoplasia/immaturity
Lung hypoplasia occurs on the ipsilateral side of hernia-
tion, with the contralateral side being affected to a variable
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ondary to physical compression of the lung by abdominal
contents arresting lung development. Recently, a two-hit
hypothesis has been proposed based on rat model explain-
ing the lung injury in CDH [27] (Fig. 4). According to this
hypothesis, the initial insult occurs during the stages of
organogenesis resulting in bilateral hypoplasia, followed
by compression of the ipsilateral lung secondary to the
herniation of the abdominal viscera at later stages. This
theory explains the variability of lung hypoplasia on the
contralateral side. The interference results in decreased
branching of the bronchioles and pulmonary vessels lead-
ing to acinar hypoplasia [28, 29]. The terminal bronchioles
are decreased with thickening of alveolar septa. The lung
is relatively immature [28] and hypoplasia of pulmonary
vasculature leads to PPHN.
Pulmonary hypertension in CDH
In CDH, the total pulmonary vascular bed is reduced
with decreased number of vessels per unit of lung. In
addition, pulmonary vascular remodeling with medial
hyperplasia and peripheral extension of the muscle layer
into small arterioles is evident [30–32]. The paucity of
pulmonary vasculature and remodeling of the vessels
contribute to the ‘fixed’ or irreversible component of
PPHN in CDH [33, 34]. Altered vasoreactivity possibly
due to an imbalance of autonomic innervation (in-
creased sympathetic and decreased parasympathetic)Fig. 3 Anatomical and radiological features of CDH – A defect in the diaph
cavity. Left sided hernias are common (85%) which results in herniation of
organs. Herniation of viscera into the thoracic cavity results in abnormal lun
contralateral side. The effect of abnormal lung development on the contra
mediastinal shift. Pulmonary hypoplasia results in abnormal pulmonary vasc
ventricular dysfunction. This is more pronounced after transitioning from fe
compression in left sided hernia and secondary to low ventricular volumes
the air and fluid filled loops of bowels on the left side of the thorax with th
towards the right side signifying mediastinal shift. (Copyright Satyan Lakshm[35], and/or impaired endothelium-dependent relaxation
of pulmonary arteries [36, 37] or an imbalance between
vasoconstrictor and vasodilator mediators may contrib-
ute to the reversible component of PPHN [35, 38]. Fol-
lowing birth, a combination of pulmonary arterial
hypertension, right ventricular hypertrophy and/or fail-
ure, and left ventricular hypoplasia with pulmonary ven-
ous hypertension results in severe PPHN unresponsive
to conventional management [39].
Ventricular dysfunction
Ventricular dysfunction is observed in some patients with
severe PPHN due to CDH. During fetal life, the ductus
arteriosus serves as a pop-off value and limits right ven-
tricular strain. After birth, remodeled pulmonary vascula-
ture in CDH results in pulmonary hypertension and leads
to right ventricle (RV) dysfunction. This is more pro-
nounced after birth when there is excessive strain on the
right ventricle. Abnormalities of the left ventricle (LV)
have been reported in infants with CDH [26, 40]. When
compared to neonates with other causes of PPHN, infants
with left sided CDH had significantly lower left ventricular
mass assessed by echocardiography. Reduced left ventricu-
lar output has been documented in left sided and right
sided CDH [41]. The reduced left ventricular mass
contributes to functional LV hypoplasia and may result in
increased left atrial pressure and pulmonary venous hyper-
tension (Fig. 5) [42].ragm causes the abdominal viscera to herniate into the thoracic
both small and large intestines along with solid intra-abdominal
g development on the ipsilateral side with variable effect on the
lateral side depends on the extent of herniation and the effect on
ulature resulting in persistent pulmonary hypertension leading to right
tal circulation. Left ventricular dysfunction can be secondary to direct
in right sided hernias. Pre-operative chest and abdomen x-ray shows
e endotracheal tube above the thoracic vertebra level 4 pushed
inrusimha)
Fig. 4 Two-hit hypothesis for CDH (Copyright Satyan Lakshminrusimha)
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Prenatal diagnosis by ultrasound detects more than 50% of
CDH cases at a mean gestational age of 24 weeks [43].
Three-dimensional ultrasound imaging, fetal echocardiog-
raphy and fetal magnetic resonance imaging (MRI) are
other prenatal diagnostic modalities used in assessing the
severity and outcome of CDH. Left sided CDH may be
characterized by the presence of heterogeneous mass which
may be stomach filled with fluid or intestines. In contrast,Fig. 5 Cardiovascular effects of CDH – Hypoplastic lungs secondary to hern
pulmonary vessels. This results in reduced blood supply to the hypoplastic
this effect is more pronounced resulting in pulmonary hypertension which
hypertension, there is shunting of blood from right to left across the paten
dysfunction along with left atrial dysfunction results in pulmonary venous h
presents clinically in a wide spectrum of labile pre & postductal saturationsisolated right-sided CDH is extremely difficult to diagnose
by ultrasound if the liver is the only organ that has herni-
ated. Indirect signs such as a shift in cardiac axis, identifying
the gall bladder and vasculature in the liver using Doppler
may aide in the diagnosis [44]. MRI has been found to be
useful in detecting fetal anomalies and can be a valuable ad-
junct to evaluate the position of the liver and estimating
lung volume [45, 46]. Associated cardiac and neural tube
defects may affect the outcome of infants with CDH [47].iation of abdominal viscera leads to concomitant hypoplasia of the
alveolar-capillary unit. Once the infant transitions from fetal circulation,
leads to right ventricular dysfunction. Secondary to pulmonary
t foramen ovale and the patent ductus arteriosus. Left ventricular
ypertension and worsening of pulmonary arterial hypertension. This
to profound cyanosis. (Copyright Satyan Lakshminrusimha)
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work up
Most common associated chromosomal abnormalities are
the trisomies 18, 13 and 21 [48]. Chromosomal aneu-
ploidies such as monosomy X, tetrasomy 12 p, tetraploidy
21 have also been associated with CDH [43, 48]. CDH is
the most common finding in Fryns syndrome [49]. CDH
can also be part of Pentalogy of Cantrell, Apert,
Brachmann-Cornelia De Lange, Beckwith-Wiedemann,
CHARGE, Coffin-Siris, Goldenhar sequence, Simpson-
Golabi-Behmel, Stickler, Pierre Robin sequence and VAC-
TERL [48, 50].
Once diagnosed, the patient should be referred to a ter-
tiary care center for further prenatal workup and manage-
ment. A multi-disciplinary prenatal consult involving the
obstetrics, neonatology, pediatric surgery, genetics at a
center that has expertise in managing infants with CDH
and extracorporeal membrane oxygenation (ECMO) are
imperative. In addition, if an MRI was done, radiology is
also involved in the multi-disciplinary prenatal consult.
Fetal predictors of outcomes
Major determinants of the outcomes in CDH are i) the
presence of associated anomalies especially heart disease
and ii) extent of lung hypoplasia and (iii) position of the
liver [43].Fig. 6 Lung to head ratio (LHR) measurement – Obstetric ultrasound techn
assess the severity of CDH. The head circumference is measured as shown.
and perpendicular diameter of the contralateral lung. The ratio of this area
associated with poor outcome while a ratio of >1.35 has been associated w
is used in order to overcome bias secondary to gestational age. (CopyrightThe prognosis of isolated CDH is generally better than
CDH complicated by multiple anomalies. Population-
based studies report higher survival for isolated CDH
compared to CDH with anomalies [4, 51]. Metkus et al.
reported higher survival for CDH detected after 25 weeks
by ultrasound [52]. This has not been validated and in
the true sense, herniation that occurs before 25 weeks
tends to have severe lung hypoplasia compared to her-
niation after 25 weeks [53].
Liver herniation (liver-up) is associated with worse prog-
nosis. Earlier studies have reported 100% survival without
liver herniation (liver-down) as compared to 56% with
liver herniation [52]. The survival decreased from 74 to
45% with liver herniation as reported by a meta-analysis
[54]. In another study, liver herniation was highly predict-
ive of ECMO (80% - liver-up vs. 25% - liver-down) and
survival (45% - liver-up vs. 93% liver-down) [55].
Metkus et al. [52] used the ratio of the contralateral lung
size compared with the head circumference to come up
with the lung-to-head ratio (LHR, Fig. 6) to assess the se-
verity of pulmonary hypoplasia and to predict postnatal
outcome in fetuses with CDH [52, 55, 56]. Since these
measurements differed by gestational age and were not
found to be consistent across centers [57, 58], observed to
expected lung-to–head ratio (O/E LHR) was studied
which was independent of gestational age [59]. LHR ratioique is used to measure the lung to head ratio known as LHR to
The contralateral lung area is calculated as a product of the longest
to the head circumference gives the LHR. A LHR of <0.6 has been
ith survival. Alternatively, an observed to expected LHR measurement
Satyan Lakshminrusimha)
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come (see Table 1 below)
Management
Antenatal Management – Medical
Antenatal corticosteroids are administered to mothers in
some centers to improve lung maturation in neonates
with CDH. While some animal results are promising
[60], no significant advantages are reported in human in-
fants [61]. It may be prudent to administer antenatal
corticosteroids prior to delivery of preterm infants with
CDH based on their premature gestation.
Pregnant rats with nitrofen induced CDH demonstrated
significant improvement in lung structure, increased
pulmonary vessel density, reduced right ventricular hyper-
trophy following antenatal therapy with high-dose sildena-
fil [36]. To our knowledge there are no human trials
evaluating the role of antenatal phosphodiesterase inhibi-
tors in CDH.
Antenatal Management - Surgical
Tracheal occlusion: In the surgically induced lamb model
of CDH with hypoplastic lungs, occlusion of the fetal tra-
chea led to an acceleration of lung growth. Harrison et al.
at the University of California in San Francisco (UCSF)
reported the first randomized controlled trial of open
hysterotomy-guided fetal endoscopic tracheal occlusion. No
improvement in survival was observed when compared
with conventional postnatal care. Junior et al. reported a
meta-analysis of various fetoscopic tracheal occlusion stud-
ies. Fetoscopic tracheal occlusion procedure increased neo-
natal survival at 30 days and 6 months among patients with
severe CDH. However, it was associated with higher rate of
premature rupture of membranes and decreased gestational
age at delivery by 2 weeks [62]. A new minimally invasiveTable 1 Antenatal ultrasound predictors of survival in CDH
A. LHR is calculated by dividing fetal lung area (mm2) by fetal head
circumference (mm). Fetal lung area is usually measured at the level
of the four-chamber view of the heart by multiplying the longest
diameter of the contralateral lung by its longest perpendicular
diameter. Alternatively, some obstetricians trace the lung margin and
measure the lung area. The fetal head circumference is measured by
its longest electronic ellipse.
a. LHR > 1.35 associated with 100% survival
b. LHR 1.35 to 0.6 associated with 61% survival
c. LHR < 0.6 – no survival
B. Observed to expected LHR (O/E LHR) is calculated by dividing the
observed LHR by the expected ratio for gestational age
a. The fetal lung area increases 16-fold compared to 4-fold increase
in the head circumference between 12 and 32 weeks’ gestation
b. O/E LHR < 25% is considered severe CDH (survival 10% with liver
up and 25% with liver down)
c. O/E LHR < 15% with liver up – 100% mortality
C. Position of liver (or presence of liver herniation)
a. Liver herniation with LHR < 1.0 – 60% mortality
b. Liver in the thorax – 56% survival;operation termed percutaneous fetal endoluminal tracheal
occlusion (FETO) is being subjected to randomized clinical
trials with ongoing recruitment. More information about




The timing of delivery
The optimal timing of delivery of an infant with CDH is
controversial. Stevens et al. initially reported that among
infants delivered by elective cesarean section, early term
birth (at 37–38 weeks gestation) was associated with less
use of ECMO (22 vs. 35.5%) compared to term delivery
(at 39–41 weeks) [63]. However, more recent analysis
suggested decreased mortality with advancing gestation
[64]. Among 928 infants with CDH in this review,
neonatal and infant mortality decreased from 25 and
36% respectively at 37 weeks gestation to 17 and 20% at
40 weeks gestation. We recommend delivery after com-
pletion of 39 weeks of gestation to avoid complications
associated with prematurity and early term delivery [65].
Postnatal Management – Medical (Fig. 7)
Delivery room (DR) Deliveries should be conducted at
centers with capabilities of managing an infant with
CDH and associated complications. Resuscitation in the
DR is based on neonatal resuscitation program (NRP)
guidelines [66]. All infants with CDH or suspected CDH
need an orogastric/nasogastric tube with suction to de-
compress the bowel. Bag-mask ventilation should be
avoided. The majority of these infants (especially with a
prenatal diagnosis of CDH) require intubation in the de-
livery room. A pre-ductal pulse oximeter is placed on
the right upper extremity as soon as possible. Ventilation
using a T-piece resuscitator is preferred to avoid high
airway pressures. Peak inspiratory pressure (PIP) should
be preferably below 25 cm H2O to avoid damage to the
hypoplastic/immature lung. Oxygen can be titrated to
maintain preductal saturations recommended by NRP.
In some institutions, preductal saturations > 70% are ac-
cepted for the first 1–2 h if pH and arterial carbon diox-
ide for PaCO2 are within normal limits.
Stabilization Central or peripheral venous access is
obtained for administering fluids and medications. An
arterial line for monitoring blood pressure and to draw
blood gases is needed. Although it has been traditional
to place an umbilical arterial line, it may be preferable to
obtain a preductal arterial line in the right radial or
ulnar artery. Umbilical artery line values reflect postduc-
tal arterial oxygen tension (PaO2) and lead to increased
fraction of inspired oxygen (FIO2). Systemic blood pres-
sures are maintained at normal values for gestational age
Fig. 7 Management of CDH – At birth infants with CDH or suspected CDH should have an orogastric/nasogastric tube with suction to attain
bowel decompression. Bag-mask ventilation should be avoided. The majority of these infants (especially with prenatal diagnosis of CDH) require
intubation in the delivery room. A pre-ductal pulse oximeter is placed on the right upper extremity as soon as possible. Oxygen saturation targets
are based on NRP guidelines. Ventilation using a T-piece resuscitator is preferred to avoid high airway pressures. Ventilator parameters are as
shown in the figure. Preductal blood gases and invasive blood pressure monitoring are preferred. Inhaled nitric oxide is often used for the
management of PPHN. For blood pressure management, fluid boluses and vasopressor agents are used based on the parameters in the figure.
(Copyright Satyan Lakshminrusimha)
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95%. A chest x-ray is obtained to assess the initial condi-
tion of the lung and herniated content.
Mechanical Ventilation The optimal ventilation mode
for infants with CDH and hypoplastic lungs is not
known. Many centers initiate conventional mechanical
ventilation (CMV) for respiratory support and optimize
ventilation by adjusting PIP and respiratory rate. The
recently concluded VICI (Ventilation in infants with
congenital diaphragmatic hernia) trial compared CMV
and high-frequency oscillatory ventilation (HFOV) as
the initial mode of ventilation in CDH. There was no
statistically significant difference in the combined out-
come of mortality or bronchopulmonary dysplasia (BPD)
[68]. In this study, 91 (53.2%) patients initially received
CMV and 80 (46.8%) HFOV. Forty-one patients (45.1%)
randomized to CMV died/had BPD compared with 43
patients (53.8%) in the HFOV group. An odds ratio of
0.62 [95% confidence interval (95% CI) 0.25–1.55] (P =
0.31) for death/BPD for CMV vs HFOV wasdemonstrated, after adjustment for center, LHR, side of
the defect, and liver position. Patients initially ventilated
by CMV were ventilated for fewer days (P = 0.03), less
often needed ECMO support (P = 0.007), inhaled nitric
oxide (iNO, P = 0.045), sildenafil (P = 0.004), had a
shorter duration of vasoactive drugs (P = 0.02), and
less often failed treatment (P = 0.01) as compared with
infants initially ventilated by HFOV. It is important
to note that guidelines for initial settings for CMV in
this study included low positive end-expiratory pres-
sure (PEEP) (3 to 5 cm H2O) and PIP (20 to 25 cm
H2O). These findings suggest that an initial attempt
at CMV is reasonable for patients with CDH.
A review of autopsies of 68 infants with CDH showed
significant pulmonary injury (alveolar damage, hyaline
membrane formation, pneumothoraces in 2/3 of autop-
sies) secondary to mechanical ventilation where 53 in-
fants were switched to HFOV in a median time of 15 h
from birth [69]. In view of preventing volutrauma and
barotrauma, a gentler approach to ventilation is pre-
ferred in infants with CDH. CMV mode [70, 71] with
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targeting preductal saturations of >85%, post-ductal sat-
urations of >70% and PaCO2 of 45–60 mmHg are used
to initiate ventilation. Many centers switch to HFOV or
jet ventilation as a rescue therapy if the ventilator targets
cannot be achieved on CMV. The settings on HFOV are
not well defined. Mean airway pressure (MAP) is usually
adjusted to maintain adequate inflation of the contralat-
eral lung to 8 ribs in a range of 13–17 cm H2O [71–73].
The role of surfactant Although animal studies strongly
suggest the presence of an immature lung with surfac-
tant deficiency, a retrospective analysis failed to support
any beneficial effect of surfactant replacement therapy in
term infants with CDH [74]. Its use in preterm infant
was also associated with lower survival rate [75]. How-
ever, this trial by its retrospective nature may be biased
as sicker patients may have received surfactant Although
there are no increasing trends in use of surfactant, it is
still being used in preterm infants with CDH across
centers [76]. Prospective trials are needed to evaluate
the benefits of surfactant in infants with CDH. The
beneficial effect of surfactant cannot be ruled out in a
premature lung and it is unclear if there is a direct
causal association between surfactant administration and
mortality in infants with CDH.
Hemodynamic monitoring and management Invasive
blood pressure (BP) monitoring is preferred over non-
invasive monitoring. Pre and post-ductal saturations and
heart rate should be continuously monitored. Optimal
end-organ perfusion is the goal to hemodynamic moni-
toring in infants with CDH. Signs of adequate perfusion
include normal range of heart rate for gestational age,
normal capillary refill, a urine output >1.0 ml/kg/h, ar-
terial pH >7.2 and lactate levels of <3-5 mmol/L [71]. If
there are signs suggestive of poor perfusion, volume
resuscitation and vasopressor therapy should be consid-
ered. The treatment should be streamlined based on car-
diac function assessed by echocardiogram and volume
requirement. In case of hypovolemia, a bolus with an
isotonic solution like 0.9% normal saline or lactated
Ringer’s solution, 10 ml/kg intravenously can be given.
Volume resuscitation is usually followed by vasopressor/
inotropic therapy.
Vasopressor/inotropic therapy (Table 2)
Dopamine is the most commonly used cardiovascular
medication in NICU and is given as an infusion [77] aim-
ing to maintain systemic BP appropriate for gestational
age. Dobutamine is preferred in infants with poor myocar-
dial contractility. Norepinephrine and epinephrine may be
used as first line agents in some institutions secondary to
their potent vasoconstrictor activity. Epinephrine infusioncan falsely increase the lactate levels and can interfere with
management [77]. Low-dose hydrocortisone is beneficial
in vasopressor-resistant hypotension in the immediate
postnatal period [78]. Vasopressin was reported to be ef-
fective in stabilizing systemic hemodynamics in a retro-
spective chart review with decreased pulmonary/systemic
pressure ratio, in patients with CDH [79].
Management of pulmonary hypertension (Fig. 8)
PPHN in CDH infants is secondary to hypoplastic lungs
and pruned, remodeled vasculature [39, 80]. Pulmonary
arterial hypertension along with left ventricular hypopla-
sia and right ventricular hypertrophy and/or failure
complicated by pulmonary venous hypertension results
in severe PPHN not responsive to conventional therapy.
Due to right to left shunting, pre and postductal satur-
ation difference may be observed. The absence of a
difference does not rule out pulmonary hypertension. In
some patients with CDH the immediate postnatal phase,
there is a short period of better oxygenation referred to
as “honeymoon” period [39]. However, progressive de-
terioration in oxygenation is commonly observed with
deteriorating PPHN. An echocardiogram is the best
non-invasive test to assess cardiac function and pulmon-
ary pressures in an infant with CDH and is usually done
within the first 24 h and followed up as needed [81].
If preductal saturations decreases below 85%, ventila-
tion adjustments and hemodynamic management take
precedence prior to initiating any therapy. Measures to
increase systemic blood pressure may minimize the
right-to-left shunting. However, there is no need to in-
crease blood pressure to supranormal values if preductal
saturation remains above 80%. Catecholamines, espe-
cially dopamine, besides increasing systemic vascular re-
sistance also increases pulmonary vascular resistance
[30, 82]. The CDH consortium recommends maintaining
arterial blood pressure at normal levels for gestational
age if preductal saturations are between 80 to 95% [83].
Inhaled Nitric Oxide (iNO) is the first agent of choice
for treatment of pulmonary hypertension in infants
>34 weeks’ gestation. It is a selective pulmonary vaso-
dilator and relaxes pulmonary vascular smooth muscle
cells. The criteria for initiating iNO is based on the
severity of PPHN as assessed by the oxygenation index
(OI). (Note: oxygenation index (OI), = Mean airway
pressure x FiO2 x 100 ÷ PaO2). Oxygen saturation index
(OSI) is a non-invasive means of estimating oxygenation
status and can be used in the absence of an arterial
blood gas but requires further validation [84, 85]. It is
calculated using the following formula: Oxygen satur-
ation index (OSI) =Mean airway pressure x FiO2 x 100
÷ preductal SpO2). Studies in the past have reported a
mean OI of 25±9 as the cut off for initiation of iNO
[86]. Currently, in neonates with PPHN not due to
Table 2 Vasoactive medications commonly used in CDH: Typical doses, route of administration of inotropic and vasodilator
medications in the management of CDH
Drug Route Units Initial dose Maintenance Dose range
DOPAmine IV μg/kg/min 1 to 5 1 to 50 (usually 2.5 to 20)
DOBUTamine IV μg/kg/min 1 to 5 1 to 40 (usually 2.5 to 20)
EPInephrine IV μg/kg/min 0.05 to 0.1 0.1 to 1
NOREPInephrine IV μg/kg/min 0.05 to 0.1 0.05 to 2
PGE1 – Alprostadil IV μg/kg/min 0.05 to 0.1 0.01 to 4
PGE1 – Alprostadil Inhaled μg/kg/min 0.15 to 0.3 0.15 to 0.3
Milrinone IV μg/kg/min 0.25 to 0.75 (some units use a load of 50 μg/kg) 0.25 to 1
Dexamethasone IV mg/kg/dose 0.05 to 0.6 0.05 to 0.6
Hydrocortisone IV mg/kg/dose 1 to 5 0.5 to 5
Nitric oxide (NO) Inhaled Ppm 5 to 20 1 to 80
Vasopressin IV Units/kg/min 0.0001 to 0.002 0.0001 to 0.008
Prostacyclin (Epoprostenol - Flolan) IV ng/kg/min 1 to 3 50 to 80
Prostacyclin (Epoprostenol - Flolan) Inhaled ng/kg/min 50 25 to 50
Prostacyclin (Treprostinil – Remodulin) SQ or IV ng/kg/min 1.25 to 2 50 to 80
Prostacyclin (Treprostinil – Remodulin) Inhaled μg/breath 6
Prostacyclin (Iloprost) Inhaled μg/breath 2.5 or 5
Prostacyclin (Beraprost) PO μg 80 80 to 120 (adult dose)
Sildenafil IV mg/kg/h 0.14 for 3 h 0.07
Bosentan PO mg/kg/dose 1 to 2 1 to 2
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evidence of right-to-left shunting by clinical exam (a pre -
postductal saturation difference of ≥10%) [71] [87] [80]
and/or echocardiographic evidence of extrapulmonary
right to left shunting [88]. The typical initial dose is 20Fig. 8 Management of pulmonary hypertension in CDH: pulmonary vasodi
acetylcholine, Ca- calcium, cAMP - cyclic adenosine monophosphate, cGMP
endothelial nitric oxide synthase, ET – endothelin, EP – prostaglandin E rec
prostaglandin I, sGC - soluble guanylyl cyclase, PDE – phosphodiesterase inparts per million (ppm) [89] although variable dosing has
been mentioned in the literature. A complete response to
iNO is considered to be an increase in the ratio of arterial
oxygen tension (PaO2) to fraction of inspired oxygen
(FiO2) by ≥20 mmHg post iNO therapy [80].lators and nitric oxide – prostacyclin – endothelin pathways. AC –
– cyclic guanosine monophosphate, COX – cycloxygenase, eNOS –
eptor, IP – prostacyclin I receptor, NO – nitric oxide, PGI –
hibitor (Copyright Satyan Lakshminrusimha)
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iNO did not reduce the need for ECMO or death in a pro-
spective, randomized trial in infants with CDH [90]. The
ventilation approach, choice of ventilator and the OI at
enrollment in this study were different from current prac-
tice [33]. In spite of this negative study, iNO continues to
be used in US tertiary centers in the management of
infants with CDH without a change in ECMO utilization
or mortality [91]. If there is no response to iNO after opti-
mizing ventilation and hemodynamic status, iNO is grad-
ually weaned. Some patients decompensate and become
hypoxemic with discontinuation of iNO. In these in-
stances, iNO is weaned to a low dose for a few hours and
then discontinued.
The rationale for continuing vs. weaning off iNO when
there is no response is unclear. Continuing iNO with
high oxygen could be detrimental. Nitric oxide is a free
radical and can combine with superoxide anions to form
peroxynitrite, which is a toxic vasoconstrictor. Thus,
continuing iNO therapy in the absence of response re-
mains controversial.
Infants with corrected CDH are at risk for late pul-
monary hypertension. Inhaled nitric oxide may play an
important role in treating exacerbations of pulmonary
hypertension in these patients [88] [92, 93].
Prostaglandin (PGE1) intravenous (IV) PGE1 has been
used in infants with CDH especially in the setting of
right heart failure [94]. A trial of PGE1 to reopen the
ductus may reduce the load on the right ventricle. Some
groups have suggested starting PGE1 infusion when the
duration of right-to-left shunting through the ductus
arteriosus was longer than left to right shunting [95]. In
patients with ductal-dependent critical congenital heart
disease associated with CDH, IV PGE1 is necessary to
maintain ductal patency. Inhalational PGE1 is also used
as an alternative agent in treating PPHN in infants with
CDH [96]. These are non-FDA approved therapies and
lack evidence.
Prostacyclin (PGI2) is commonly used in adults may be
useful in the management of late pulmonary hyperten-
sion in infants post CDH repair. Currently, there is no
evidence to support this therapy but some centers use it
as a second-line pulmonary vasodilator. Prostacyclin can
be used as an inhaled agent or an intravenous agent.
Three forms of prostacyclin are used in the management
of pulmonary hypertension (Table 2). Epoprostenol
(Flolan), Treprostinil (Remodulin) and inhaled Iloprost
(Ventavis - inhaled prostacyclin analog) are approved for
adults with pulmonary arterial hypertension.
Sildenafil is a phosphodiesterase (PDE) 5 inhibitor that
inhibits cyclic guanosine monophosphate (cGMP) deg-
radation leading to vasodilation. Oral sildenafil improves
oxygenation and reduces mortality in PPHN in centers
limited by non-availability of iNO and ECMO [97, 98].IV sildenafil was shown to be effective in improving oxy-
genation in patients with PPHN with and without prior
exposure to iNO [99]. There are no trials to support its
use in infants with CDH. A chronic sildenafil trial was
planned in CDH infants but is currently terminated
and not recruiting patients (NCT00133679). As per
FDA, high mortality is associated with its use in
pediatric patients (1–17 y of age) with pulmonary ar-
terial hypertension [100]. Parents should be informed
about the benefits and side-effects of sildenafil prior
to initiation for chronic use in CDH.
Milrinone is a PDE 3 inhibitor which increases cyclic
adenosine monophosphate (cAMP) concentration in
smooth muscle and myocardium. It has both lusitropic
and inotropic properties. In a fetal lamb model of PPHN,
milrinone relaxed pulmonary arteries [101] and reduced
pulmonary arterial pressure. The benefits of milrinone
in children following surgery for congenital heart disease
have been well established [102]. Multiple case series
have shown IV milrinone to be effective in treating in-
fants with iNO resistant PPHN [103, 104–106]. Milri-
none therapy has been used in the management of iNO
resistant PPHN in infants with CDH. Hypotension is a
clinical concern and the infants should be monitored
closely. Despite lack of evidence, the use of milrinone in
the management of infants with CDH has increased
[76]. A loading dose (50 μg/kg for 30–60 min) followed
by a maintenance dose (0.33 μg/kg per minute and es-
calation to 0.66 and then to 1 μg/kg per minute based
on response) are commonly used. The loading dose of
milrinone will increase the risk of hypotension but may
achieve steady state plasma levels sooner [107]. Hence,
the loading dose is not recommended in the presence of
systemic hypotension in patients with CDH [108]. Some
clinicians administer a volume bolus prior to the loading
dose of milrinone to avoid systemic hypotension.
A multicenter trial investigating the use of milrinone
in infants with CDH has been proposed by the NICHD
Neonatal Research Network and will begin enrollment
shortly (NCT02951130).
Bosentan is a blocker of endothelin receptors and is
occasionally used as an oral agent in the management of
chronic pulmonary hypertension in CDH. There is lim-
ited experience with its use in neonates [109]. Liver
function tests should be closely followed during its use.
Extracorporeal membranous oxygenation (ECMO) is
considered as the last lifesaving option for infants ≥
34 weeks’ gestation or with weight >2 kg with CDH and
no associated major lethal anomalies after conventional
medical management has failed. Strong evidence for
ECMO is lacking although the number of infants with
CDH who undergo ECMO treatment has not decreased.
Selection criteria for ECMO varies across centers and re-
mains controversial. The Euro consortium experts have
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institutional variability but the following approach seems
reasonable – (a) Inability to maintain preductal satura-
tions >85% or postductal saturations >70% along with (b)
increased PaCO2 and respiratory acidosis with pH <7.15
despite optimal ventilator management, (c) PIP of >28 cm
H2O or MAP >17 cm H2O to achieve saturations >85%,
(d) inadequate oxygen delivery with metabolic acidosis, (e)
systemic hypotension resistant to fluid and pressor ther-
apy resulting in urine output <0.5 ml/kg/h for a 12–24 h
period and (f) consistently elevated OI ≥ 40.
Venoarterial (VA) ECMO is preferred in the presence of
cardiovascular compromise. There is a shift towards in-
creased use of venovenous (VV) ECMO in patients with
CDH and has comparable mortality rates [110, 111].
Functionally VA ECMO has the advantage of decreasing
the load on the right side of the heart. However, VV
ECMO allows oxygenated blood to flow through pulmon-
ary circulation resulting in enhanced pulmonary vasodila-
tion while preserving the carotid arteries. In addition,
maintaining pulsatile flow with oxygenated blood may im-
prove coronary perfusion and cardiac function with VV
ECMO. Failure of VV ECMO and a switch to VA ECMO
may be required in some patients.
Duration of treatment on ECMO is a subject of de-
bate. Congenital Diaphragmatic Hernia Study Group
retrospective data from 1995–2004 showed increased
survival in infants treated for 9 days compared to 14 days
[112]. A single institution 19-year retrospective review
concluded that in patients with severe CDH, improve-
ment in pulmonary function sufficient to wean from
ECMO can take 4 weeks or longer and might need a
second ECMO run [113]. The study reported survival
rates based on the duration of ECMO run as 56% for
2 weeks, 46% for 3 weeks, 43% for 4 weeks after which
the survival dropped to 15%. 44% (7/16) of infants who
were treated on the second run of ECMO survived.
ELSO registry data [112] shows an increase in mortality
for ECMO duration > 2 weeks. Prolonged duration of
ECMO is a predictor of mortality [112, 114].
Postnatal management - Surgical
When considering repair of the CDH, the surgeon faces
three questions: a) what is the benefit; b) when is the op-
timal time; and c) what is the best approach? The first
question, although philosophical, is critical. Our under-
standing of the benefits of repair are incomplete, but
most literature supports the idea that reduction of the
herniated visceral contents from the thoracic cavity and
closure of the diaphragmatic defect are important in the
long-term but provide little immediate benefit to the
patient [115]. Reducing herniated contents back to the
abdomen to permit expansion of the compressed lungs
does not result in immediate improvement in PPHN andhypoxemia. Pulmonary hypertension is, however, the
“rate-limiting” disease process in CDH and rarely does
hernia reduction/repair significantly improve outcome
by itself. This is particularly important as the surgical
stress of operation is often severe enough to induce pul-
monary hypertensive crises in the sicker patients, and if
undertaken in a patient while on ECMO, can lead to se-
vere hemorrhagic complications.
Optimal timing of CDH repair can be difficult to de-
termine, particularly in patients who require ECMO. For
those patients not requiring ECMO, repair is usually
offered no sooner than 48–72 h after birth, with the as-
sumption that these patients’ pulmonary vasculature is
not so compromised as to pose a significant risk of peri-
or postoperative decompensation. Once a patient re-
quires ECMO, the decision process becomes more diffi-
cult. There are generally three approaches: early repair,
immediately after ECMO initiation (typically <72 h); de-
layed repair, often done as a last-hope operation in the
setting of inability to wean off ECMO; and repair after
decannulation [116]. The data on the influence of timing
of repair on outcomes are hampered by limited num-
bers, retrospective design, patient group heterogeneity,
and thus do not serve well to inform the decision in a
generalizable and reliable manner. In broad strokes, best
outcomes appear to be in patients repaired after decan-
nulation (technically, these may be repaired the day
prior to anticipated decannulation, but in a patient who
has improved while on ECMO). Following this, those pa-
tients repaired shortly after cannulation do better than
those repaired after several weeks on ECMO. Improve-
ments in the medical treatment and prevention of bleed-
ing diatheses while on ECMO, and improved ECMO
circuits, have helped to mitigate some of the lethal
bleeding complications of repair on ECMO.
Surgical approach
Repair of the CDH may be accomplished through a thor-
acic or abdominal approach, and may be performed in an
open or minimally invasive manner. Long-term outcomes
depend, perhaps most importantly, on the characteristics
of the diaphragmatic defect. Patients with a small muscu-
lar defect that is easily approximated primarily should
have negligible recurrence rates and complications. There
has been an increasing trend toward thoracoscopic re-
pairs, which are thought to minimize post-operative pain
and scarring and hasten recovery. Several series have dem-
onstrated higher recurrences rates through the thoraco-
scopic approach, although these may have been biased by
higher rates of unfavorable anatomy and an inherent
learning curve [117]. Patients at the other end of the
spectrum, with diaphragmatic agenesis, uniformly require
placement of a patch to close the diaphragmatic defect
(Fig. 9a & b). These are typically made of synthetic
Fig. 9 a Left sided diaphragmatic hernia showing the hypoplastic left
lung, inferior muscle edge of the diaphragm and reduced viscera.
b Prosthetic patch – Gore-Tex patch used to close the defect
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growing recent interest in combining synthetic materials
with additional biologic layers in an effort to buttress the
repair and promote native tissue ingrowth for long-term
stability [118]. Lastly, several groups have lauded the bene-
fits of autologous, muscle flap closure of the defect [119].
Follow-up and outcomes
Infants with CDH face considerable long-term respira-
tory issues, nutritional problems, neurodevelopmental
delays, hernia recurrence and orthopedic deformities
[120]. The American Academy of Pediatrics (AAP) came
out with guidelines for follow-up of infants who are dis-
charged with CDH [120]. A multidisciplinary approach
with long-term follow-up is required for these infants.
Respiratory morbidities include chronic lung disease,
rebound pulmonary hypertension, obstructive pulmonary
disease and infection. Treatment with ECMO and patch re-
pair were associated with more significant pulmonary mor-
bidity [121] with decreased inspiratory muscle strength.Adolescent survivors often-faced mild to moderate ob-
structive disease requiring bronchodilator therapy along
with weak inspiratory muscle strength [122]. Nutritional
problems include gastro esophageal reflux [123, 124] aver-
sion to oral feeds, gastrostomy tube feeding and failure to
thrive. Neurological and development problems range from
physical disability to neurocognitive and functional delays.
Hearing loss is common in these infants [125, 126]. Ortho-
pedic deformities such as pectus and scoliosis are seen in
patients post CDH repair [122, 127].
Conclusion
Despite the unclear etiology of CDH and management of
PPHN, over the past few decades, reports have suggested
increasing trends of survival in infants with CDH [76].
With the medical and surgical advances in the manage-
ment of CDH, the reported overall survival is 70-90% [7,
76, 128]. With ECMO, the survival is around 50% [112–
114] with different centers reporting different criteria and
outcomes. Multiple factors such as prematurity, ECMO,
associated abnormalities especially cardiac, need for trans-
port, severity of PPHN, type of repair can affect the out-
come and survival of an infant with CDH [51, 114, 128,
129].
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